Misplaced Pages

Marine bacteriophage: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 16:07, 26 March 2008 editTemperate phage (talk | contribs)42 edits Ecology of marine bacteriophages← Previous edit Revision as of 02:00, 30 March 2008 edit undoTemperate phage (talk | contribs)42 edits ReferencesNext edit →
Line 63: Line 63:
== References == == References ==


'''''Under construction'''''
Afanasieva T, Wittmer M, Vitaliti A, Ajmo M, Neri D, Klemenz R (2003) Single-chain antibody and its derivative directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther 21:1850-1859.

Ahmad S, (2002) Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypotheses 4:327-331.

Almquist K, McLean M, Niu Y, Byrne G, Olea-Popelka F, Murrant C, Barclay J, Hall J (2006) Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco. Vaccine 12:2079-2086.

Atterbury R, Van Bergen M, Ortiz F, Lovell M, Harris J, De Boer A, Wagenaar J, Allen V, Barrow P (2007) Bacteriophage therapy to reduce Salmonella colonization of broiler chickens. Appl Environ Microbiol 14:4543-4549.

Basner-Tschakarjan E, Mirmohammadsadegh A, Baer A, Hengge U (2004) Uptake and trafficking of DNA in keratinocytes: evidence for DNA-binding proteins. Gene Ther 9:765-774.

Baucheron S, Imberechts H, Chaslus-Dancia E, Cloeckaert A (2002) The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist –Mechan Epidemiol Dis 4:281-289.

Biswas B, Adhya S, Washart P, Paul B, Trostel A, Powell B, Carlton R, Merril C (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 1:204-210.

Bockmann M, Drosten M, Putser B (2005) Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med 2:179-188.

Brockmann M, Hilken G, Schmidt A, Cranston A, Tannapfel A, Drosten, M, Frilling A, Ponder B, Putzer B (2005) Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Hum Gene Ther 11:1267-1275.

Broxmeyer L, Sosnowska D, Miltner E, Chacon O, Wagner D, McGarvey J, Barletta R, Bermudez L (2002) Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: A model for phage therapy of intracellular bacterial pathogens. J Infect Dis 8:1155-1160.

Bruins M, Fernandes T, Ruijs G, Wofhagen M, van Rijn-van Berkel J, Schenk B, van Duynhoven Y (2003) Detection of a nosocomial outbreak of salmonellosis may be delayed by application of a protocol for rejection of stool cultures. J Hosp Infect 2:93-98.

Bruttin A, Brussow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 7:2874-2878.

Burnie J, Carter T, Rigg G, Hodgetts S, Donohoe M, Matthews R (2002) Identification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy. FEMS Immunol Med Microbiol 3:179-189.

Carrillo C, Atterbury R, El-Shibiny A, Connerton P, Dillon E, Scott A, Connerton I (2005) Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl Environ Microbiol 11:6554-6563.

Celer V Blazek D, Navratilova I, Skladal P, Blacklaws B, Bujdoso R (2003) Recombinant single-chain Fv antibodies that recognize the p25 protein of the Maedi-Visna virus. Folio Microbiol 3:435-440.

Cerveny K, DePaola A, Duckworth D, Gulig P (2002) Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 11:6251-6262.

Chen L, Thung S, Woo S (2007) Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Mol Ther 6: 1079-1085.

Chen L, Woo S (2007) Correction in female PKU mice by repeated administration of mPAH cDNA using phiBT1 integration system. Mol Ther 10:1789-1795.

Chen Z, He C, Kay M (2005) Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 1:126-131.

Chibani-Chennoufi S, Sidoti J, Bruttin A, Dillmann M, Kutter E, Qadri F, Sarker S, Brussow H (2004) Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol 24:8287-8294.

Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brussow H (2004) In vitro and in vivo bacteriolytic activities of Escherichia coli phages: Implications for phage therapy. Antimicrob Agents Chemother 7:2558-2569.

Ciuffi A, Diamond T, Hwang Y, Marshall H, Bushman F (2006) Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factor. Hum Gene Ther 9:960-967.

Connerton P, Carrillo C, Swift C, Dillon E, Scott A, Rees C, Dodd C, Frost J, Connerton I (2004) Longitudinal study of Campylobacter jejuni bacteriophages and their hosts from broiler chickens. Appl Environ Microbiol 7:3877-3883.

Danelishvili L, Young L, Bermudez L (2006) In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. Microb Drug Resist-Mechan Epidemiol Dis 1:1-6.

Davern S, Foote L, Lankford T, Macy S, Wall M, Kennel S (2005) Identification of an antilaminin-1 scFv that preferentially homes to vascular solid tumors. Cancer Biother Radiopharm 5:524-533.

De Bernardis F, Liu H, O’Mahony R, La Valle R, Bartollino S, Sandini S, Grant S, Brewis N, Tomlinson I, Basset R, Holton J, Roitt I, Cassone A (2007) Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 1:149-157.

Ehrhardt A, Engler J, Xu H, Cherry A, Kay M (2006) Molecular analysis of chromosomal rearrangements in mammalian cells after phi C31-mediated integration. Hum Gene Ther 11:1077-1094.

Ehrhardt A, Xu H, Huang Z, Engler J, Kay M (2005) A direct comparison of two nonviral gene therapy vectors for somatic integration: In vivo evaluation of the bacteriophage integrase phi c31 and the Sleeping Beauty transposase. Mol Ther 5:695-706.

Ernst R, D’Argenio D, Ichikawa J, Bangera M, Selgrade S, Burns J, Hiatt P, McCoy K, Brittnacher M, Kas A, Spencer D, Olson M, Ramsey B, Lory S, Miller S (2003) Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ Microbiol 12:1341-1349.

Falke D, Juliano R (2003) Selective gene regulation with designed transcription factors: Implications for therapy. Curr Opin Mol Ther 2:161-166.

Fortin M, Orlava A, Malstrom P, Tolmachev V (2007) Labelling chemistry and characterization of -DOTA-Z(HER2 : 342)-3 affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 2:285-291.

Gadea I, Cuenca-Estrella M, Prieto E, Diaz-Guerra T, Garcia-Cia J, Mellado E, Tomas J, Rodriguez-Tudela J (2004) Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hemotological patients of a tertiary hospital. J Clin Microbiol 4:1832-1836.

Gill J, Pacan J, Carson M, Leslie K, Griffiths M, Sabour P (2006) Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents Chemother 9:2912-2918.

Gill J, Sabour P, Leslie K, Griffiths M (2006) Bovine whey proteins inhibit the interaction of Staphylococcus aureus and bacteriophage K. J Appl Microbiol 2:377-386.
Goni F, Sigurdsson E (2005) New directions towards safer and effective vaccines for Alzheimer’s disease. Curr Opin Mol Ther 1:17-23.

Goode D, Allen V, Barrow P (2003) Reduction of experimental Salmonella and Campylobacter contamination of chicken skin by application of lytic bacteriophages. Appl Environ Microbiol 8:5032-5036.

Griggs D, Johnson M, Frost J, Humphrey T, Jorgensen F, Piddock L (2005) Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment. Antimicrob Agents Chemother 2:699-707.

Groot A, Verheesen P, Westerlaken E, Gort E, van der Groep P, Bovenschen N, van der Wall E, van Diest P, Shvarts A (2006) Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha. Lab Invest 4:345-356.

Gunderson C, Segall A (2006) DNA repair, a novel antibacterial target: Holliday junction-trapping peptides induce DNA damage and chromosome segregation defects. Mol Microbiol 4:1129-1148.

Guo S, Tschammer N, Mohammed S, Guo P (2005) Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 9:1097-1109.

Hagens S, Blasi U (2003) Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 4:318-323.

Hagens S, Habel A, Blasi U (2006) Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microb Drug Resist-Mechan Epidemiol Dis 3:164-168.

Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U (2004) Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 10:3817-3822.

Hammerschmidt S, Hacker J, Hacker J, Klenk H (2005) Threat of infection: Microbes of high pathogenic potential – strategies for detection, control and eradication. Int J Med Microbiol 3:141-151.

Harcombe W, Bull J (2005) Impact of phages on two-species bacterial communities. Appl Environ Microbiol 9:5254-5259.

Held P, Olivares E, Aguilar C, Finegold M, Calos M, Grompe M (2005) In vivo correction of murine hereditary tyrosinemia type 1 by phi C31 integrase-mediated gene delivery. Mol Ther 3:399-408.

Henry T, Pommier S, Journet L, Bernadac A, Gorvel J, Lloubes R (2004) Improved methods for producing outer membrane vesicles in Gram-negative bacteria. Res Microbiol 6:437-446.

Hoeprich S, Zhou Q, Guo S, Shu D, Qi G, Wang Y, Guo P (2003) Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther 15:1258-1267.

Horwacik I, Czaplicki D, Talarek K, Kowalczyk A, Bolesta E, Kozbor D, Rokita H (2007) Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library. Int J Mol Med 5:829-839.

Ishikawa Y, Tanaka N, Murakami K, Uchiyama T, Kumaki S, Tsuchiya S, Kugoh H, Oshimura M, Calos M, Sugamura K (2006) Phage phi C31 integrase-mediated integration of the common cytokine receptor gamma chain in human T-cell lines. J Gene Med 5:646-653.

Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P (2003) Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrobial Chemother 6:967-973.

Jamalludeen N, Johnson R, Friendship R, Kropinski A, Lingohr E, Gyles C (2007) Isolation and characterization of nine bacteriophages that lyse O149 enterotoxigenic Escherichia coli. Vet Microbiol 1-2:47-57.

Kellogg C, Rose J, Jiang S, Thurmond J, Paul J (1995) Genetic diversity of related vibriophages isolated from marine environments around Florida and Hawaii, USA. Mar Ecol Prog Ser 120:89-98.

Kervala A, Portlock J, Nash A, Vitrant D, Robbins P, Calos M (2006) PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints. J Gene Med 8:1008-1017.

Kolonin M, Saha P, Chan L, Pasqualini R, Arap W (2004) Reversal of obesity by targeted ablation of adipose tissue. Nat Med 6:625-632.

Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M, Bottex C, Thullier P (2005) Selection of macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 8:3414-3420.

Leszczynski P, Weber-Dabrowski B, Kohutnicka M, Luczak M, Gorecki A, Gorski A (2006) Successful eradication of methicillin-resistant staphylococcus aureus (MRSA) intestinal carrier status in healthcare worker - Case report. Folia Microbiol 3:236-238.

Lionakis M, Lahdenranta J, Sun J, Liu W, Lewis R, Albert N, Pasqualini R, Arap W, Kontoyiannis D (2005) Development of a ligand-directed approach to study the pathogenesis of invasive apergillosis. Infect Immun 11:7747-7758.

Liu A, Hu P, Khawli L, Epstein A (2006) B7.1/NHS76: A new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother 4:425-435.

Loeffler J, Djurkovic S, Fischetti V (2003) Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 11:6199-6204.

Machold K, Smolen J (2003) Adalimumab – a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 2:351-360.

Martinez M, Clotet B (2003) Genetic screen for monitoring hepatitis C virus NS3 serine protease activity. Antimicrob Agents Chemother 5:1760-1765.

Maruta F, Parker A, Fisher K, Hallissey M, Ismail T, Rowlands D, Chandler L, Kerr D, Seymour L (2002) Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 6:543-552.

McGuire M, Samli K, Chang Y, Brown K (2006) Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp Hematol 4:443-452.

McIntosh R, Shi J, Jennings R, Chappel J, de Koning-Ward T, Smith T, Green J, van Egmond M, Leusen J, Lazarou M, van de Winkel J, Jones T, Crabb B, Holder A, Pleass R (2007) The importance of human Fc gamma RI in mediating protection to malaria. PLoS Pathog 5:647-658.

McLaughlin M (2007) Simple colorimetric microplate test of phage lysis in Salmonella enterica. J Microbiol Methods 2:394-398.

McVay C, Velasquez M, Fralick J (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 6:1934-1938.

Meulenbroek R, Sargent K, Lunde J, Jasmin B, Parks R (2004) Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 4:617-624.

Nejatollahi F, Hodgetts S, Vallely P, Burnie J (2002) Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol Med Microbiol 3:237-244.

Nicklin S, White S, Nichol C, Von Seggern D, Baker A (2004) In vitro and in vivo characterization of endothelial cell selective adenoviral vectors. J Gene Med 3:300-308.

Ochoa T, Chen J, Walker C, Gonzales E, Cleary T (2007) Rifaximin does not induce toxin production of phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 8:2837-2841.

Pameijer C, Navanjo A, Meechoovet B, Wagner J, Aguilar B, Wright C, Chang W, Brown C, Jensen M (2007) Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther 1:91-97.

Paradis-Bleau C, Cloutier I, Lemieux L, Sanschagrin F, Laroche J, Auger M, Garnier A, Levesque R (2007) Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage phi KZ gp144 lytic transglycoslylase. FEMS Microbiol Lett 2:201-209.

Platt R, Reynolds D, Phillips G (2003) Development of a novel method of lytic phage delivery by use of a bacteriophage P22 site-specific recombination system. FEMS Microbiol Lett 2:259-265.

Portlock J, Calos M (2003) Site-specific genomic strategies for gene therapy. Curr Opin Mol Ther 4:376-382.

Portlock J, Keravala A, Bertoni C, Lee S, Rando T, Calos M (2006) Long-term increase in mVEGF164 in mouse hindlimb muscle mediated by phage phi C31 integrase after nonviral DNA delivery. Hum Gene Ther 8:871-876.

Przerwa A, Zimecki M, Switala-Jelen K, Dabrowska K, Krawczyk E, Luczak M, Weber-Darowska B, Syper D, Miedzybrodzki R, Gorski A (2006) Effects of bacteriophages on free radical production and phagocytic functions. Med Microbiol Immunol 3:143-150.

Quenneville S, Chapdelaine P, Rousseau J, Beaulieu J, Caron N, Skuk D, Mills P, Olivares E, Calos M, Tremblay J (2004) Nucleofection of muscle-derived cells and myoblasts with phi C31 integrase: Stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol Ther 4:679-687.

Resch A, Fehrenbacher B, Eisele K, Schaller M, Gotz F (2005) Phage release from biofilm and planktonic Staphylococcus aureus cells. FEMS Microbiol Lett 1:89-96.

Rodriguez-Cerrato V, Garcia P, Huelves L, Garcia E, del Prado G, Gracia M, Ponte C, Lopez R, Soriano F (2007) Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly beta-lactam-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 9:3371-3373.

Rybniker J, Kramme S, Small P (2006) Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis – application for identification and susceptibility testing. J Med Microbiol 1:37-42.

Sanz L, Kristensen P, Blanco B, Facteau S, Russel S, Winter G, Alvarez-Vallina L (2002) Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther 15:1049-1053.

Scheppler L, Vogel M, Marti P, Muller L, Miescher S, Stadler B (2005) Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease. Vaccine 9:1126-1134.

Sheng H, Knecht H, Kudva I, Hovde C (2006) Application of bacteriophages to control intestinal Escherichia coli O157 : H7 levels in ruminants. Appl Environ Microbiol 8:5359-5366.

Sirakova T, Dubey V, Cynamon M, Kolattukudy P (2003) Attenuation of Mycobacterium tuberculosis by disruption of a mas-like gene or a chalcone synthase-like gene, which causes deficiency in dimycocerosyl phthiocerol synthesis. J Bacteriol 10:2999-3008.

Stevenson G (2006) CD38 as a therapeutic target. Mol Med 11-12:345-346.

Takac M, Blasi U (2005) Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 7:2934-2940.

Ulasov I, Tyler M, Han Y, Glasgow J, Lesniak M (2007) Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha 2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 2:118-129.

Vellani T, Myers R (2003) Bacteriophage SPP1 Chu is an alkaline exonuclease in the SynExo family of viral two-component recombinases. J Bacteriol 8:2465-2474.

Verthe K, Verstraete W (2006) Use of flow cytometry for analysis of phage-mediated killing of Enterobacter aerogenes. Res Microbiol 7:613-618.

Waldor M, Friedman D, Adhya S eds. (2005) Phage ecology and bacterial pathogenesis. In Phages: their role in bacterial pathogenesis and biotechnology pp 66-84. Washington DC: ASM Press.

Walter M, Baker D (2003) Three Bacillus anthracis bacteriophages from topsoil. Curr Microbiol 1:55-58.

Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong H, Li Q, Hu J (2006) Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med 2:347-355.

Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong H, Li Q, Hu J (2006) Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 2:309-317.

Waterkamp D, Muller O, Ying Y, Trepel M, Kleinschmidt J (2006) Isolation of targeted AAV(2) vectors from novel virus display libraries. J Gene Med 11:1307-1319.

Weber-Dabrowska B, Zimecki M, Mulczyk M, Gorski A (2002) Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol Med Microbiol 2:135-138.

Westwater C, Kasman L, Schofield D, Werner P, Dolan J, Schmidt M, Norris J (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 4:1301-1307.

Wills Q, Kerrigan C, Soothill J (2005) Experimental bacteriophage protection against Staphylococcus aureus abscesses in rabbit model. Antimicrob Agents Chemother 3:1220-1221.

Wommack K, Hill T, Muller A, Colwell R (1996) Effects of sunlight on bacteriophage viability and structure. Appl Environ Microbiol 62:1336-1341.

Work L, Buning H, Hunt E, Nicklin S, Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M, Baker A (2006) Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 4:683-693.

Work L, Nicklin S, Brain N, Dishart K, Von Seggern D, Hallek M, Buning H, Baker A (2004) Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2:198-208.

Wu M, Pasula R, Smith P, Martin W (2003) Mapping alveolar binding sites in vivo using phage peptide libraries. Gene Ther 17:1429-1436.



== See also == == See also ==

Revision as of 02:00, 30 March 2008

What is a bacteriophage?

Discovered in 1915 by Frederick W. Twort, and independently in 1917 by Félix d’Herelle (a then somewhat obscure researcher at the Pasteur Institute in Paris), bacteriophages are ubiquitous and in numbers difficult to comprehend, but estimated at around 10 in total. Their importance in ecosystems, particularly marine ecosystems, has only recently been comprehended.

In the simplest terms, bacteriophages or "phages" are viruses which attack only bacteria. Like all viruses, bacteriophages share broad similarities of structure and function. There are differences, however, based on the particular strain of virus or the mode of reproduction (lytic or lysogenic, or a combination of these). All phages are obligate parasites of bacteria. All, in some form or another, possess genes (which code for structural proteins as well various enzymes) enclosed in a capsid, as well as tails and other structures used to penetrate the host.

Phages can be divided according to what form their genetic material is stored (RNA or DNA, single-stranded or double-stranded, circular or linear). There are some general patterns and loose rules regarding relationships between lifestyle and structure. Filamentous phages (which lack tails and appear as thin tubes) are always lysogenic. T4, the most commonly recognized phage (at least to non-specialists), exhibits a prolate head and a contractile tail in the classical “spaceship” form, often (and mistakenly) seen as the epitome of the viral shape. T4 is lytic, but not all lytic phages exhibit a similar structure. Many are spherical or icosahedral, lacking any discernable tail. These globular phages tend to possess the greatest quantity of genetic information, but again, this is not a concrete pattern.


Phage biology: lysis mechanisms

With few exceptions (e.g. filamentous temperate phages), all viruses of bacteria ultimately lyse their hosts to release virion particles. The phenomenon of lysis is therefore universal. However, as will be evidenced, this does not mean that the process is simple or even similar among phage species. Temperate (lysogenic) phages appear to utilize a relatively recently evolved life strategy toward mutualism. Interestingly, they still retain the genetic capacity to produce endolytic enzymes along with concomitant or accessory molecules (which control the timing and strength of lysis).

Broadly speaking, there are two methods by which bacteriophages lyse their hosts. Both weaken and ultimately destroy the bacterial cell wall by interfering with the protein murein.

The first method, and by far the most common, is to actively degrade the protein murein, causing the localized weakness and eventual rupturing of the entire bacterium by internal osmotic pressure. To date, four independently evolved muralytic enzymes have been identified: endopeptidase, amidase, glycosidase, and transglycosylase. Some phages of gram-positive bacteria use forms of lysozymic endopeptidase to attack peptide linkages in oligopeptide cross-links. Others express the T7 lysozyme, gp3.5, which acts as an amidase to destroy the molecular connection between MurNac and the cross-linking oligopeptide. The phage λ utilizes the lysis gene e, which expresses glycosidase. This is related to and shares a cell-wall substrate with transglycosylase, which is expressed by the T4 lysis gene R. Glycosidase hydrolyzes the GlcNac-MurNac glycosidic bond, whereas transglycosylase degrades the same bond using an internal nucleophile rather than water (producing cyclic end-products in the process.

The second, least common and perhaps more genetically complicated method, is to prohibit or prevent the bacterium from repairing or synthesizing the cell wall. In this sense, then, the phage directs its attack not on the cell wall but on the bacterial mechanisms for murein production. Three phages have been shown to lack endolytic activity: single-stranded RNA Фx174, as well as the alloleviruses Qβ and MS2. Instead, with the exception of MS2 (whose function remains a mystery) they express amurins, which act to inhibit various enzymes in the murein synthesis pathway.

With regard to active bacterial cell wall degradation, phage mechanisms are not as straightforward or simple as involving the expression of lytic enzymes alone. An essential component is lysis timing and the means which have evolved to control it. Phages express a very diverse family of proteins known as holins, which act to stimulate or aid the secretion of endolytic enzymes across the bacterial plasma membrane(s), allowing active lysis.

The “logic” of evolution indicates the utility of these proteins. Slow, steady production and secretion of lytic enzymes would allow only the localized or slow secretion of virions because cell-wall degradation would be countered by the repair efforts of the bacterium. Instead of countering these efforts, exhausting the host in the process and possibly lowering virion assembly rates, the phage induces (through holin production) a build-up of muralytic enzymes behind the cytosolic plasma membrane. Upon the appropriate timing or environmental signal (such as a chemotactic indication that there are more hosts in the vicinity ripe for infection) holins trigger a massive release of enzymes from the plasma membrane. The cell wall is bombarded by this influx, causing an immediate and irreparable lysis.

Holins are small membrane proteins, divided into three classes based on topology. Class I holins possess three transmembrane domains (TMD) with the amino group (N) out, and the carboxyl group (C) in. Class II holins possess two TMDs (N out; C in), while class III holins reveal one TMD (N in; C out). Each phage typically expresses but one class of holin, which is incorporated into the bacterial plasma membrane during virion morphogenesis and muralytic enzyme production. These accumulate within the plasma membrane at the same time as muralytic enzymes amass in the cytoplasm. At the trigger point (determined by holin concentration), the plasma membrane lyses, allowing migration of muralytic enzymes and subsequent contact with wall substrates.

Holins are unique in that, unlike other cytolytic toxins, they are able to accumulate within the cytoplasm of the host until the appropriate environmental or timing cue is received. Both the biochemical means by which holins transform from harmless molecules to cytolytic enzymes (based on conformational changes) and the mechanism controlling the timing of the process remain unclear at present.

Experiments which have studied the in vitro lyse rate of particular phage treatments against their natural bacterial hosts always reveal a massive and instantaneous lysis of the host bacteria, causing immediate, observable plaques to form on prepared cultures.


The microbial loop

Under construction

Ecology of marine bacteriophages

If they can be described as being “alive,” marine phages, although invisible and essentially unnoticed by scientists until very recently, are the most abundant and diverse form of life on the planet. They influence biogeochemical cycles globally, provide and regulate microbial diversity, cycle carbon through marine food webs, and are essential in preventing bacterial population explosions.

Aquatic phages in general are evident in historical accounts: the mythical healing powers of the Ganges River, for example, were not fictional. However, their curative effects were less the benevolence of a Hindu deity than bacteriolytic phages.

Because there are estimated to be on average 10 phages per mL sea water (with 10 phage infections occurring in the world per second), and because every one of these infections allows the opportunity for genetic recombination, it may be concluded that both phage and bacteria have evolved effective and successful means of maintaining and exploiting environmentally-adaptive alleles.

Bacteria are continually exposed, in the form of bacteriophage infections, to selective pressures encouraging better defences against viral attack. They undergo genetic recombination by three seemingly improvised, if effective, mechanisms: transformation (whereby the bacterium transports genetic material into its genome from the external environment), conjugation (in which the transfer of genetic material between bacteria), and transduction (whereby genetic material is passed from bacterium to bacterium by bacteriophages).

Phages, which generally reproduce clonally, depend for genetic recombination on utilizing strands of genetic material found in their hosts. These are derived from prophages already present in the host genome. It is also possible that different lytic phages which infect the bacterium at similar times (i.e. before lysis occurs) are able to trade genes. Such notions are bolstered by the fact that bacteriophages exhibit genetic mosaicism, whereby comparative analysis of different phages reveals strands of closely related genes intermittently broken by strands of different genes. The comparative ratio of phage to bacteria makes phage genetic recombination highly successful. It also allows greater degree of adaptability: those virions which transcribe adaptive genes are bestowed an immediate selective advantage compared to other virions released by the same lytic event, which transcribe less adaptive genes.

Besides this apparent benefit, phages are slightly advantaged in their coevolutionary relationship with bacteria (but obviously not excessively so) because they are much smaller than their hosts, because they have shorter generation times, and because there are so many more of them.

Marine phage applications and geoengineering

As scientists begin to understand phages, their potential becomes clearer. Bacteriophages have been suggested primarily as an organic alternative to antibiotics. However, they may also be utilized in future geoengineering experiments.

Marine cyanophages can be used to prevent or reverse eutrophication, for example, if properly utilized against blue-green algae.

External bacteriophage links

Marine Microbiology Group at the College of Marine Science, University of South Florida

Bacteriophage Ecology Group, Ohio State University

Viral Bioinformatics Resource Center, University of Victoria

References

Under construction

See also